Mechanism of Action
Once ingested, GOS resist gastric digestion and small intestine enzymes. They reach the colon intact. There, specific bacterial families possess the enzymes needed to break them down. This process, called selective fermentation, produces short-chain fatty acids (molecules with two, three or four carbons). Butyrate provides energy to the cells lining the colon wall. These cells form a barrier between intestinal contents and the bloodstream. The more intact this barrier, the fewer unwanted molecules pass through.
The growth of beneficial bacteria acidifies the intestinal environment. This lower pH inhibits potentially harmful species. The prebiotic effect reshapes the entire ecosystem, beyond merely feeding a few strains.
Key Benefits
- Strong
Multiple controlled trials show a reproducible increase in colonic bifidobacteria within the first week of GOS supplementation in healthy adults.
- Strong
Adult clinical trials report improved stool frequency and consistency with GOS, with a dose-dependent effect.
- Moderate
A double-blind randomized trial in adults over 65 showed increased phagocytic activity and immune markers after eight weeks of GOS.
- Moderate
A controlled study measured by isotope tracer an increase in calcium absorption with GOS in adolescent girls.
- Moderate
A three-week randomized trial observed reduced waking salivary cortisol in healthy volunteers supplemented with GOS, suggesting an effect on the gut-brain axis.
- Emerging
Preliminary clinical data indicate a modest reduction in total cholesterol and triglycerides with GOS in short-duration trials.
Dosage & Forms
Commercial GOS vary in their polymerisation profile. Short chains (DP2-3) dominate the market, while extended-spectrum blends (DP2-8) show a more pronounced bifidogenic effect in clinical trials. The literature uses doses ranging from 2.5 g to 15 g per day. The consensus for a significant bifidogenic effect in adults is around 5 to 5.5 g per day. This is the dose used in the main randomized trials.
Gradual increase over five to seven days limits initial digestive discomfort. Singular calibrates the dose based on individual profile and other fibers present in the formula.
In the Singular Formula
Inclusion rationale
Non-digestible prebiotic fibers produced by enzymatic transgalactosylation of lactose. GOS (galacto-oligosaccharides) are structurally similar to human milk oligosaccharides (HMOs), the natural fibers that shape the infant microbiota from the very first hours of life. Not digested in the small intestine, GOS reach the colon intact where they are selectively fermented by bifidobacteria and lactobacilli, the bacterial genera that are pillars of a balanced microbiota. This fermentation produces short-chain fatty acids (butyrate, propionate, acetate), energy sources for colonocytes and modulators of intestinal pH. Butyrate nourishes the cells of the colonic mucosa and contributes to intestinal barrier function. GOS differ from FOS (fructo-oligosaccharides) in their galactosidic structure, which gives them superior digestive tolerance with less bloating. In the formula, GOS selectively feed Bifidobacterium lactis (present in the formula), while Bacillus subtilis (also present) brings complementary microbial diversity through its spore form. Acacia fiber adds gradual prebiotic fermentation. This network approach aims to support microbiota diversity, whose decline is a marker of biological aging.
Selected form
Galacto-oligosaccharides (GOS) in soluble fibre form, produced by enzymatic transgalactosylation of lactose. GOS are prebiotics: non-digestible fibres that serve as a selective substrate for beneficial gut bacteria, particularly bifidobacteria. This concentrated form contains a spectrum of oligosaccharide chains from DP2 to DP8 (degree of polymerisation from 2 to 8 galactose units). Slightly sweet taste, good solubility. May contain traces of residual lactose. Quality: non-GMO.
Formula dosage
0 to 5 g.
Synergies in the formula
Safety & Precautions
GOS have a long history of safe use. Naturally present in breast milk as structurally similar oligosaccharides, they are part of human nutrition from birth. Clinical trials report a favorable tolerance profile at studied doses (up to 15 g per day). Adverse effects are limited to mild bloating or flatulence, transient and reduced by gradual introduction over five to seven days.
Individuals with significant lactose sensitivity should note the possible presence of residual traces. GOS are not recommended for people with galactosemia (a rare genetic condition that prevents galactose metabolism). Pregnant or breastfeeding women can consume GOS as part of a balanced diet. For any specific health situation, consulting a healthcare professional is recommended.
Scientific Studies
| Authors | Year | Type | Journal | |
|---|---|---|---|---|
| Vulevic J et al. | 2013 | Randomised Controlled Trial | The Journal of Nutrition | View on PubMed |
A mixture of trans-galactooligosaccharides reduces markers of metabolic syndrome and modulates the fecal microbiota and immune function of overweight adults Double-blind randomized trial in 45 overweight adults: GOS supplementation reduces inflammatory markers, total cholesterol and favorably modulates fecal microbiota. | ||||
| Vulevic J et al. | 2008 | Randomised Controlled Trial | The American Journal of Clinical Nutrition | View on PubMed |
Modulation of the fecal microflora profile and immune function by a novel trans-galactooligosaccharide mixture (B-GOS) in healthy elderly volunteers Double-blind randomized trial in 44 healthy volunteers over 64: GOS (5.5 g/d, 10 weeks) increase bifidobacteria and improve phagocytic activity. | ||||
| Schmidt K et al. | 2015 | Randomised Controlled Trial | Psychopharmacology | View on PubMed |
Prebiotic intake reduces the waking cortisol response and alters emotional bias in healthy volunteers Randomized trial in 45 healthy volunteers: three weeks of GOS reduce waking salivary cortisol and decrease attentional bias toward negative stimuli. | ||||
| Whisner CM et al. | 2013 | Randomised Controlled Trial | British Journal of Nutrition | View on PubMed |
Galacto-oligosaccharides increase calcium absorption and gut bifidobacteria in young girls: a double-blind cross-over trial Double-blind crossover trial in adolescent girls: GOS increase calcium absorption measured by isotope tracer and fecal bifidobacteria. | ||||
| Silk DB et al. | 2009 | Randomised Controlled Trial | Alimentary Pharmacology & Therapeutics | View on PubMed |
Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome Clinical trial in 44 individuals with functional bowel disorders: GOS (3.5 g/d then 7 g/d) increase bifidobacteria and improve subjective intestinal comfort. | ||||
| Davis LM et al. | 2011 | Randomised Controlled Trial | PLoS ONE | View on PubMed |
Barcoded pyrosequencing reveals that consumption of galactooligosaccharides results in a highly specific bifidogenic response in humans Study using pyrosequencing in 18 healthy adults: GOS produce a highly specific bifidogenic response, selectively increasing certain bifidobacterial species. | ||||
| Davani-Davari D et al. | 2019 | Systematic Review | Foods | View on PubMed |
Prebiotics: Definition, Types, Sources, Mechanisms, and Clinical Applications Comprehensive review of prebiotics including GOS: selective fermentation mechanisms, clinical data on bifidogenic and immunomodulatory effects in humans. | ||||